| |
|
|
|
|
|
 |
| |
|
¾ØÁö´ýÆÐÃë0.2mg/½Ã°£ ANGIDERM PATCH 0.2mg/hr
|
|
Àü¹®ÀǾàǰ | »èÁ¦
|
|
|
| |
 |
¾Ë¸²: |
µå·°ÀÎÆ÷¿¡¼´Â ÀǾàǰ ÀÎÅÍ³Ý ÆÇ¸Å¸¦ ÇÏÁö ¾Ê½À´Ï´Ù. |
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
À¯·áȸ¿ø °áÀç½Ã¿¡´Â º¸´Ù ´Ù¾çÇÑ ¾à¹°Á¤º¸¸¦
ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ½À´Ï´Ù.
À¯·áÁ¤º¸¸ñ·ÏÀº Àü¹®È¸¿øÀ¸·Î
·Î±×ÀÎ ÇϽøé È®ÀÎ °¡´ÉÇÕ´Ï´Ù.
|
|
|
 | Çã°¡Á¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
û±¸ÄÚµå(KDÄÚµå) ºñ±Þ¿©Á¡°ËÄÚµå »óÇÑ±Ý¾× |
640100110[A63200071]
[º¸ÇèÄڵ忡 µû¸¥ ¾àǰ±âº»Á¤º¸ Á÷Á¢Á¶È¸]
\0 ¿ø/1¸Å(2012.09.01)(ÇöÀç¾à°¡)
\669 ¿ø/1¸Å(2012.07.01)(º¯°æÀü¾à°¡)
[»óº´ÄÚµåÁ¶È¸]
[Áúº´ÄÚµåÁ¶È¸]
|
| ºü¸¥Á¶È¸ |
|
| Á¦Ç°¼º»ó |
»óºÎ´Â ¹ÝÅõ¸íÇÑ Çʸ§ÀÌ ¾à¹°ÀúÀåºÎ Á¢ÂøÁ¦¿Í ºÎÂøµÇ¾î ÀÖÀ¸¸ç ÇϺδ Åõ¸íÇÑ Çʸ§À¸·Î µ¤¿©ÀÖ´Â °¢ÀÌ µÕ±Û°í ³×¸ð³ ÆÐÃë Á¦Á¦ÀÌ´Ù. [Á¦ÇüÁ¤º¸ È®ÀÎ] |
| Æ÷À塤À¯Åë´ÜÀ§ |
2, 10, 30, 100EA
|
| Æ÷À塤ÄÚµå´ÜÀ§ |
| ¾àǰ±Ô°Ý |
´ÜÀ§ |
Æ÷ÀåÇüÅ |
´ëÇ¥ÄÚµå |
Ç¥ÁØÄÚµå |
ºñ°í |
| 65¹Ð¸®±×·¥ |
1 ¸Å |
ÆÑ |
8806401001101 |
8806401001125 |
|
| 65¹Ð¸®±×·¥ |
30 ¸Å |
ÆÑ |
8806401001101 |
8806401001118 |
|
|
| ÁÖ¼ººÐÄÚµå |
202504CPC
[µ¿ÀÏÇÑ ÁÖ¼ººÐÄڵ带 °¡Áø ¿À¸®Áö³¯ ¶Ç´Â Á¦³×¸¯ ÀǾàǰ Á¶È¸]
|
| Çã°¡»çÇ× ¿ø¹®Á¶È¸ |
[Çã°¡»çÇ× ¿ø¹®Á¶È¸]
|
| È¿´ÉÈ¿°ú |
[ÀûÀÀÁõ º° °Ë»ö]
Çù½ÉÁõ
|
| ¿ë¹ý¿ë·® |
* Àý´ë ÀÓÀǺ¹¿ëÇÏÁö ¸¶½Ã°í ¹Ýµå½Ã ÀÇ»ç ¶Ç´Â ¾à»ç¿Í »ó´ãÇϽñ⠹ٶø´Ï´Ù.
[󹿾à¾î]
1. ¼ºÀÎ: 1ȸ 1¸Å(´ÏÆ®·Î±Û¸®¼¼¸°À¸·Î¼ 5-10mg/24½Ã°£)ÀÇ ÆÐÃ븦 »ç¿ëÇÑ´Ù.
2. ÈäºÎ, »óº¹ºÎ, ¹èºÎ, »ó¿ÏºÎ, ´ëÅðºÎ µî ÅÐÀÌ ¾ø´Â ÇǺΠǥ¸é¿¡ Á÷Á¢ »ç¿ëÇϸç ÅÐÀÌ ÀÖ´Â ºÎºÐÀº ¸éµµ ÈÄ ºÎÂøÇÑ´Ù.
3. ÀÎüÀÇ ¸»ÃʺÎÀ§³ª »çÁö µî °úµµÇÏ°Ô ¿òÁ÷ÀÌ´Â °÷¿¡´Â ºÎÂøÇÏÁö ¾Ê´Â´Ù.
4. ÇǺΠÀÚ±ØÀ» ÁÙÀ̱â À§ÇØ ºÎÂø Àå¼Ò¸¦ ¸Å¹ø ¹Ù²ãÁØ´Ù.
5. ´À½¼ÇÏ°Ô ºÎÂøµÇ¾ú°Å³ª ¶³¾îÁø °æ¿ì »õ°ÍÀ¸·Î ¹Ù²ã ºÎÂøÇÑ´Ù.
6. ÀÓ»óÈ¿°ú, ºÎÀÛ¿ë, Ç÷¾Ð¹× ½É¹Ú¼ö µî¿¡ µû¶ó ÃÖÀû¿ë·®À» °áÁ¤ÇÑ´Ù.
7. ¹æÃâ·® 5mg/24½Ã°£ ¼ÒÇü ÆÐÃë·Î ½ÃÀÛÇÏ°í °í¿ë·®ÀÌ ÇÊ¿äÇÑ °æ¿ì ¹æÃâ·® 10mg/24½Ã°£ ´ëÇü ÆÐÃ븦 »ç¿ëÇÏ´Â °ÍÀÌ ¹Ù¶÷Á÷ÇÏ´Ù.
8. ´ÏÆ®·Î±Û¸®¼¼¸°ÀÇ È¿°úÀûÀÎ »ç¿ëÀ» °í·ÁÇÏ¿©, »ç¿ëµµÁß ÈÞ¾à±â(8~12½Ã°£)¸¦ °í·ÁÇÑ´Ù.
|
| ±Ý±â |
1) Áú»ê¿°Á¦Á¦¿¡ °ú¹ÎÁõ ¹× ±× º´·ÂÀÌ Àִ ȯÀÚ
2) ÁßÁõÀÇ ºóÇ÷ ȯÀÚ
3) µÎºÎ¿Ü»ó ¶Ç´Â ³úÃâÇ÷ ȯÀÚ(µÎ°³³»¾ÐÀ» »ó½Â½Ãų ¼ö ÀÖ´Ù.)
4) Æó¼â¿ì°¢Çü ³ì³»Àå ȯÀÚ
5) ÁßÁõÀÇ ÀúÇ÷¾Ð, ½ÉÀμº ¼ï ȯÀÚ
6) ±Þ¼º ¼øÈ¯±â Àå¾Ö(¼îÅ©, ¼øÈ¯±â ¼îÅ©)
7) ÀÌ ¾àÀ» PDE-5 ÀúÇØÁ¦(¿¹: ¾Æ¹Ù³ªÇÊ, ½Çµ¥³ªÇÊ, ¹Ùµ¥³ªÇÊ, Ÿ´Ù¶óÇÊ, À¯µ¥³ªÇÊ, ¹Ì·Îµ¥³ªÇÊ µî)¿Í sGC ÀÚ±ØÁ¦(soluble Guanylate Cyclase Stimulator)(¿¹: ¸®¿À½Ã±¸¾Ñ µî)¸¦ »ç¿ë ÁßÀΠȯÀÚ¿¡°Ô Åõ¿©Çؼ´Â ¾È µÈ´Ù.
|
| ½ÅÁßÅõ¿© |
1) ÀúÇ÷¾Ð ȯÀÚ
2) ±Þ¼º ½É±Ù°æ»ö, ¿ïÇ÷¼º ½ÉºÎÀü ȯÀÚ (¼¼¹ÐÇÑ ÀÓ»ó°Ë»ç ¶Ç´Â Ç÷¾×µ¿·ÂÇÐÀû °Ë»çÈÄ »ç¿ëÇÑ´Ù).
3) ±â¸³¼º Á¶ÀýÀå¾Ö ȯÀÚ
|
| ÀÌ»ó¹ÝÀÀ |
1) ¼øÈ¯±â°è : ¶§¶§·Î ½É°èÇ×Áø, Ç÷¾Ð°ÇÏ, µå¹°°Ô ¾îÁö·¯¿ò, ¿°¨, ±â¸³¼º ÀúÇ÷¾Ð, ½É¹ÚÃâ·®ÀúÇÏ, ºó¸Æ, ¼¸Æ µîÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
2) Á¤½Å½Å°æ°è : µÎÅë, ¶§¶§·Î µÎÁß µîÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
3) ¼Òȱâ°è : µå¹°°Ô ±¸¿ª, ±¸Åä µîÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
4) ÇǺΠ: ¶§¶§·Î ºÎÂøºÎÀ§ÀÇ °¡·Á¿ò, Á¢Ã˼º ÇǺο°, ¹ßÀû, ¹ßÁø, ÇǺÎÀڱذ¨ µîÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
5) ±âŸ : µå¹°°Ô ¹«·Â°¨, Àü½Å±Çۨ, ±¸°¥ µîÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
|
| »óÈ£ÀÛ¿ë |
1) ¾Æ½ºÇǸ° ¹× ±âŸ ºñ½ºÅ×·ÎÀ̵强 ¼Ò¿°ÁøÅëÁ¦°¡ ÀÌ ¾àÀÇ ÀÛ¿ëÀ» °¨¼Ò½Ãų ¼ö ÀÖ´Ù.
2) ´Ù¸¥ Ç÷°üÈ®ÀåÁ¦, Ä®½·±æÇ×Á¦, »ïȯ°è Ç׿ì¿ïÁ¦ ¹× ¾ËÄڿðúÀÇ º´¿ë¿¡ ÀÇÇØ Ç÷¾Ð°ÇÏÀÛ¿ëÀÌ Áõ°µÉ ¼ö ÀÖ´Ù.
3) PDE-5 ÀúÇØÁ¦(Phosphodiesterase type 5 inhibitor)¿Í sGC ÀÚ±ØÁ¦(soluble Guanylate Cyclase Stimulator)
¨ç ÀÌ ¾àÀº PDE-5 ÀúÇØÁ¦(¿¹, ¾Æ¹Ù³ªÇÊ, ½Çµ¥³ªÇÊ, ¹Ù¸£µ¥³ªÇÊ, Ÿ´Ù¶óÇÊ, À¯µ¥³ªÇÊ, ¹Ì·Îµ¥³ªÇÊ µî)¿Í º´¿ëÇØ¼´Â ¾ÈµÈ´Ù. ÀÌ ¾à°ú º´¿ë ½Ã PDE-5 ÀúÇØÁ¦´Â À¯±â Áú»ê¿°Á¦Á¦ÀÇ ÀúÇ÷¾Ð È¿°ú¸¦ °È½ÃŲ´Ù.
¨è ÀÌ ¾àÀº sGC ÀÚ±ØÁ¦(¿¹: ¸®¿À½Ã±¸¾Ñ µî)°ú º´¿ëÇØ¼´Â ¾ÈµÈ´Ù. ÀÌ ¾à°ú º´¿ë ½Ã ÀúÇ÷¾ÐÀ» ¾ß±âÇÒ ¼ö ÀÖ´Ù.
¨é ÀÌ·¯ÇÑ »óÈ£ÀÛ¿ë¿¡ ´ëÇÑ ½Ã°£, ¿ë·® ÀÇÁ¸¼ºÀº ¿¬±¸µÇÁö ¾Ê¾ÒÀ¸¹Ç·Î ¼öÀÏ À̳»·Î º´¿ë Åõ¿©ÇÏ´Â °ÍÀº ±ÇÀåÇÏÁö ¾Ê´Â´Ù. ÁßÁõÀúÇ÷¾ÐÀÇ ÀûÀýÇÑ ÁöÁö¿ä¹ý¿¡ ´ëÇÑ ¿¬±¸´Â ¼öÇàµÇÁö ¾Ê¾ÒÁö¸¸, ¼Õ¹ß µé¾î¿Ã¸² ¹× Á᫐ ¿ëÀû È®´ë(central volume expansion) óġ¸¦ ÇÏ´Â °ÍÀÌ ÀûÀýÇÏ´Ù.
|
| Off-label Usage |
[Á¶È¸]
|
| Related FDA Approved Drug |
|
|
|
 | Á¤º¸¿ä¾à |
|
|
|
µå·°ÀÎÆ÷ ÀǾàǰ ¿ä¾à/»ó¼¼Á¤º¸
|
|
 | ÄÚµå ¹× ºÐ·ùÁ¤º¸ |
|
|
| |
|
 | Á¦Ç°Á¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
û±¸ÄÚµå(KDÄÚµå) ºñ±Þ¿©Á¡°ËÄÚµå »óÇÑ±Ý¾× |
640100110[A63200071]
[º¸ÇèÄڵ忡 µû¸¥ ¾àǰ±âº»Á¤º¸ Á÷Á¢Á¶È¸]
\0 ¿ø/1¸Å(2012.09.01)(Ãֽžడ)
\669 ¿ø/1¸Å(2012.07.01)(º¯°æÀü¾à°¡)
[»óº´ÄÚµåÁ¶È¸]
[Áúº´ÄÚµåÁý ´Ù¿î·Îµå]
|
| Á¦Ç°¼º»ó |
»óºÎ´Â ¹ÝÅõ¸íÇÑ Çʸ§ÀÌ ¾à¹°ÀúÀåºÎ Á¢ÂøÁ¦¿Í ºÎÂøµÇ¾î ÀÖÀ¸¸ç ÇϺδ Åõ¸íÇÑ Çʸ§À¸·Î µ¤¿©ÀÖ´Â °¢ÀÌ µÕ±Û°í ³×¸ð³ ÆÐÃë Á¦Á¦ÀÌ´Ù.
[Á¦ÇüÁ¤º¸ È®ÀÎ]
|
| Æ÷À塤À¯Åë´ÜÀ§ |
2, 10, 30, 100EA
|
| º¸°ü¹æ¹ý |
½Ç¿Âº¸°ü, ±â¹Ð¿ë±â. |
µ¿ÀÏÁÖ¼ººÐÄÚµå °Ë»ö¼øÀ§ |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
|
|
 | º¹¾àÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| LACTmed ¹Ù·Î°¡±â |
[¹Ù·Î°¡±â]
|
| ¾à¸®ÀÛ¿ë |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| Ãà¾àº¹¾àÁöµµ |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| º¹¾àÁöµµ |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| ÀӺο¡´ëÇÑÅõ¿© |
| * |
ÀüüÀӽŠ±â°£º°·Î ¿©·¯µî±ÞÀÌ Á¸ÀçÇÒ ¼ö ÀÖÀ¸¸ç °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ º¸¿©Áý´Ï´Ù. ´Ü, º¹ÇÕÁ¦ÀÇ °æ¿ì ¸ðµç º¹ÇÕÁ¦¼ººÐ¿¡ ´ëÇÑ ÀÓºÎÅõ¿©µî±ÞÀÌ Ç¥½ÃµÈ°ÍÀº Àý´ë ¾Æ´Ï¸ç Ç¥½ÃµÈ°ÍÁß¿¡ °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ ³ªÅ¸³³´Ï´Ù.
|
|
|   |
 FDA : Cµî±Þ
|
|
| * |
»ó±â ÀÓºÎÅõ¿©¿¡ ´ëÇÑ Á¤º¸´Â Àü»êó¸® µÇ¸é¼ ÀÔ·Â ¿À·ù °¡´É¼ºÀÌ Á¸ÀçÇÕ´Ï´Ù. ¿À·ù °¡´É¼ºÀ» ÃÖ¼ÒÈÇϱâ À§ÇÏ¿© ¸¹Àº ³ë·ÂÀ» ±â¿ïÀ̰í ÀÖÀ¸³ª, ±× Á¤È®¼º¿¡ ´ëÇÏ¿© È®½ÅÀ» µå¸± ¼ö ¾ø½À´Ï´Ù. ÀÌ¿¡ ´ëÇØ ȸ»ç´Â Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù.
|
| * |
¹Ýµå½Ã °ø½Å·Â ÀÖ´Â ¹®ÇåÀ» ´Ù½Ã Çѹø Âü°í ÇϽñ⠹ٶó¸ç ÀÇ»ç ¶Ç´Â ¾à»çÀÇ ÆÇ´Ü¿¡ µû¶ó Åõ¿©¿©ºÎ°¡ °áÁ¤µÇ¾î¾ß ÇÕ´Ï´Ù.
|
|
|
| Pharmacokinetics |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| º´¿ë±Ý±â ¹× ¿¬·É´ë±Ý±â ±Ù°ÅÁ¶È¸ |
[º´¿ë±Ý±â ¹× ¿¬·É´ë±Ý±â ±Ù°ÅÁ¶È¸]
|
| º¹¾à¶óº§ |
| À̹ÌÁö |
º¹¾à¼³¸í |
 |
¾îÁö·¯¿òÀÌ ÀÖÀ»¼ö ÀÖ½À´Ï´Ù. |
|
|
| * |
º¹¾àÀ̹ÌÁö´Â ¸ðµç º¹¾àÁöµµ »çÇ×À» Ç¥½ÃÇѰÍÀº ¾Æ´Ï¸ç, Ãß°¡ÀûÀ¸·Î ¾÷µ¥ÀÌÆ®µÇ°Å³ª ¼öÁ¤µÉ ¼ö ÀÖ½À´Ï´Ù. |
| * |
º¹¾àÀ̹ÌÁöÀÇ Ç¥½Ã¿©ºÎ´Â ½ÇÁ¦ ¾à¹°º¹¿ë½Ã Á߿䵵¿¡ µû¸¥°ÍÀº ¾Æ´Ï¸ç ´Ü¼øÈ÷ Çã°¡Á¤º¸»ó Ű¿öµå¸¦ ±âÁØÀ¸·Î µî·ÏµÇ¾ú½À´Ï´Ù. |
| * |
±ÍÇϰ¡ º¹¾àÀ̹ÌÁö Á¤º¸¸¦ ½Å·ÚÇÔÀº ÀüÀûÀ¸·Î ±ÍÇÏÀÇ Ã¥ÀÓÀÔ´Ï´Ù. µå·°ÀÎÆ÷´Â ÀÌ¿¡ ´ëÇÑ ¾î¶°ÇÑ º¸Áõµµ ÇÏÁö ¾Ê½À´Ï´Ù. |
|
|
| Á¦Çüº° º¹¾àÁöµµ |
[ÆÐÃë] |
| º¸°ü»ó ÁÖÀÇ |
|
| Á¶Á¦½Ã ÁÖÀÇ |
|
|
|
 | ½É»çÁ¤º¸ |
|
|
|
|
 | ÇмúÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| DUR (ÀǾàǰ»ç¿ëÆò°¡) |
º´¿ë±Ý±â :
°í½ÃµÈ º´¿ë±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[»óÈ£ÀÛ¿ë/º´¿ë±Ý±â°Ë»ö]
¿¬·É´ë±Ý±â :
°í½ÃµÈ ¿¬·É±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[¿¬·É´ë±Ý±â»ó¼¼°Ë»ö]
|
| ÈÇб¸Á¶ ¹× ¹°¼º |
[Nitroglycerin]
 [Nitroglycerin] CAS number/55-63-0 PubChem/4510 Chemical formula/C3H5(NO3)3
|
| µ¶¼ºÁ¤º¸ |
Glycerin¿¡ ´ëÇÑ µ¶¼ºÁ¤º¸ : Á¤º¸º¸±â
Nitroglycerin¿¡ ´ëÇÑ µ¶¼ºÁ¤º¸ : Á¤º¸º¸±â
Ãâó: ±¹¸³µ¶¼º°úÇпø µ¶¼º¹°ÁúÁ¤º¸DB : http://www.nitr.go.kr/nitr/contents/m134200/view.do |
| Mechanism of Action |
Nitroglycerin¿¡ ´ëÇÑ Mechanism_Of_Action Á¤º¸ Similar to other nitrites and organic nitrates, nitroglycerin is converted to nitric oxide (NO), an active intermediate compound which activates the enzyme guanylate cyclase. This stimulates the synthesis of cyclic guanosine 3',5'-monophosphate (cGMP) which then activates a series of protein kinase-dependent phosphorylations in the smooth muscle cells, eventually resulting in the dephosphorylation of the myosin light chain of the smooth muscle fiber. The subsequent release of calcium ions results in the relaxation of the smooth muscle cells and vasodilation.
|
| Pharmacology |
Nitroglycerin¿¡ ´ëÇÑ Pharmacology Á¤º¸ Nitroglycerin, an organic nitrate, is available in many forms as a vasodilator. Nitroglycerin is used in the treatement of angina pectoris and perioperative hypertension, to produce controlled hypotension during surgical procedures, to treat hypertensive emergencies, and to treat congestive heart failure associated with myocardial infarction.
|
| Metabolism |
Nitroglycerin¿¡ ´ëÇÑ Metabolism Á¤º¸ # Phase_1_Metabolizing_Enzyme:Not Available
|
| Protein Binding |
Nitroglycerin¿¡ ´ëÇÑ ´Ü¹é°áÇÕ Á¤º¸ Not Available
|
| Half-life |
Nitroglycerin¿¡ ´ëÇÑ ¹Ý°¨±â Á¤º¸ 3 minutes
|
| Absorption |
Nitroglycerin¿¡ ´ëÇÑ Absorption Á¤º¸ Not Available
|
| Pharmacokinetics |
NitroglycerinÀÇ ¾à¹°µ¿·ÂÇÐÀÚ·á
- ÀÛ¿ë¹ßÇö½Ã°£ ¹× ÀÛ¿ëÁö¼Ó½Ã°£ : Á¦Çü¿¡ µû¶ó ´Ù¸§

- ´Ü¹é°áÇÕ : 60%
- ´ë»ç : ÃÊȸÅë°úÈ¿°ú Å
- ¹Ý°¨±â : 1-4ºÐ
- ¼Ò½Ç : ´¢¸¦ ÅëÇØ ºñȰ¼ºÇü ´ë»çü·Î ¹è¼³
|
| Biotransformation |
Nitroglycerin¿¡ ´ëÇÑ Biotransformation Á¤º¸ Hepatic, cytochrome P450 (P450) is a key enzyme of organic nitrate biotransformation
|
| Toxicity |
Nitroglycerin¿¡ ´ëÇÑ Toxicity Á¤º¸ Increased intracranial pressure, with any or all of persistent throbbing headache, confusion, and moderate fever; Vertigo; Palpitations; Visual disturbances; Nausea and vomiting (possibly with colic and even bloody diarrhea); Syncope (especially in the upright posture); Air hunger and dyspnea, later followed by reduced ventilatory effort; Diaphoresis, with the skin either flushed or cold and clammy; Heart block and bradycardia; Paralysis; Coma; Seizures; Death.
|
| Drug Interactions |
Nitroglycerin¿¡ ´ëÇÑ Drug_Interactions Á¤º¸ Alteplase IV nitroglycerin decreases the effect of alteplaseDihydroergotamine Possible antagonism of actionDihydroergotoxine Possible antagonism of actionErgonovine Possible antagonism of actionErgotamine Possible antagonism of actionMethylergonovine Possible antagonism of actionMethysergide Possible antagonism of actionSildenafil Possible significant hypotension with this combinationTadalafil Possible significant hypotension with this combinationVardenafil Possible significant hypotension with this combination
|
CYP450 Drug Interaction |
[CYP450 TableÁ÷Á¢Á¶È¸]
|
| Food Interaction |
Nitroglycerin¿¡ ´ëÇÑ Food Interaction Á¤º¸ Avoid alcohol.Take on empty stomach: 1 hour before or 2 hours after meals.Dissolve under the tongue.
|
| Drug Target |
[Drug Target]
|
| Description |
Nitroglycerin¿¡ ´ëÇÑ Description Á¤º¸ A volatile vasodilator which relieves angina pectoris by stimulating guanylate cyclase and lowering cytosolic calcium. [PubChem]
|
| Dosage Form |
Nitroglycerin¿¡ ´ëÇÑ Dosage_Form Á¤º¸ Aerosol, metered SublingualDisc TransdermalLiquid IntravenousLiquid OralOintment TopicalPatch TransdermalSolution IntravenousSolution / drops OralSpray, metered SublingualTablet OralTablet Sublingual
|
| Drug Category |
Nitroglycerin¿¡ ´ëÇÑ Drug_Category Á¤º¸ Explosive AgentsNitrates and NitritesTocolytic AgentsVasodilator Agents
|
| Smiles String Canonical |
Nitroglycerin¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ [O-][N+](=O)OCC(CO[N+]([O-])=O)O[N+]([O-])=O
|
| Smiles String Isomeric |
Nitroglycerin¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ [O-][N+](=O)OCC(CO[N+]([O-])=O)O[N+]([O-])=O
|
| InChI Identifier |
Nitroglycerin¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ InChI=1/C3H5N3O9/c7-4(8)13-1-3(15-6(11)12)2-14-5(9)10/h3H,1-2H2
|
| Chemical IUPAC Name |
Nitroglycerin¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ 1,3-dinitrooxypropan-2-yl nitrate
|
|
|
 | »ç¿ëÀÚÄÁÅÙÃ÷ |
|
|
|
|
|
-
ÃÖ±ÙÁ¤º¸¼öÁ¤ÀÏ 2024-07-25
-
º» ¼öÁ¤ÀÏ Á¤º¸´Â Çã°¡Á¤º¸ ÀÌ¿ÜÀÇ ±âŸÁ¤º¸ ¼öÁ¤ÀÏÀ» ÀǹÌÇϹǷÎ, Çã°¡Á¤º¸¼öÁ¤ÀÏÀº º»¹®¿¡ Ç¥±âµÈ ³¯Â¥¸¦ ÂüÁ¶ÇϽñ⠹ٶø´Ï´Ù.
|
|
¾Ë¸² |
»ó¼¼Á¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×À» Åä´ë·Î ÀÛ¼ºµÇ¾úÀ¸¸ç ¿ä¾àÁ¤º¸´Â »ó¼¼Á¤º¸ ¹× ±âŸ¹®ÇåÀ» ±â¹ÝÀ¸·Î µå·°ÀÎÆ÷¿¡¼ ÆíÁýÇÑ ³»¿ëÀÔ´Ï´Ù. Á¦Ç°Çã°¡»çÇ×ÀÇ ¸ñÂ÷¿Í ´Ù¼Ò »óÀÌÇÒ ¼ö ÀÖ½À´Ï´Ù. |
|
°æ°í |
µå·°ÀÎÆ÷ ÀǾàÇмúÁ¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×, Çмú¹®Çå, Á¦¾àȸ»ç Á¦°øÁ¤º¸ µîÀ» ±Ù°Å·Î ÀÛ¼ºµÈ Âü°í Á¤º¸ÀÔ´Ï´Ù.
Á¤º¸ÀÇ Á¤È®¼ºÀ» À§ÇØ ³ë·ÂÇϰí ÀÖÀ¸³ª ÆíÁý»óÀÇ ¿À·ù, Çã°¡»çÇ× º¯°æ, Ãß°¡ÀûÀÎ Çмú¿¬±¸ ¶Ç´Â Àӻ󿬱¸ ¹ßÇ¥ µîÀ¸·Î ÀÎÇØ ¹ß»ýÇÏ´Â ¹®Á¦¿¡ ´ëÇØ µå·°ÀÎÆ÷´Â
Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù. ÀÚ¼¼ÇÑ ³»¿ëÀº ¡°Ã¥ÀÓÀÇ ÇÑ°è ¹× ¹ýÀû°íÁö¡±¸¦ ÂüÁ¶ÇØ ÁֽʽÿÀ.
¹Ýµå½Ã Á¦Á¶¡¤¼öÀÔ»ç, ÆÇ¸Å»ç, ÀÇ»ç, ¾à»ç¿¡°Ô ÃÖÁ¾ÀûÀ¸·Î È®ÀÎÇϽñ⠹ٶø´Ï´Ù.
ÀüÈ: 02-3486-1061 ¤Ó À̸ÞÀÏ: webmaster@druginfo.co.kr
|
|
¾Æ·¡ÀÇ ³»¿ëÀ» Æ÷ÇÔÇÑ Àüü µ¥ÀÌÅ͸¦ º¸½Ã·Á¸é
¿©±â·Î À̵¿ÇϽñ⠹ٶø´Ï´Ù.
º´¿ë±Ý±â ¹× ƯÁ¤¿¬·É´ë ±Ý±â ¼ººÐ
[ÀǾàǰº´¿ë/¿¬·É´ë±Ý±â °í½Ã±Ù°Å·Î ¹Ù·Î°¡±â] Á¦¸ñ ¾øÀ½
2008³â 8¿ù 1ÀÏ ¾à°¡ÈÀÏ»ó 8¿ù´Þ ½Å±ÔµîÀç ¹× »èÁ¦µÇ´Â ǰ¸ñ Æ÷ÇÔÇÑ º´¿ë¿¬·É ±Ý±â ǰ¸ñ¸®½ºÆ® ±âÁØ
1. ÇöÀç °Ë»öÇÑ Á¦Ç°¿¡ ´ëÇÑ º´¿ë±Ý±â Á¦Ç° Á¸Àç¿©ºÎ ¹× °Ë»ö
ÇöÀç ÀÌÁ¦Ç°¿¡ ´ëÇÑ º´¿ë±Ý±â¿¡ ÇØ´çÇϴ û±¸Äڵ庰 Á¦Ç°³»¿ª °øÁö³»¿ëÀÌ ¾ø½À´Ï´Ù
2. ¿¬·É´ë±Ý±â Á¸Àç¿©ºÎ
ÇöÀç ÀÌÁ¦Ç°¿¡ ´ëÇÑ ¿¬·É±Ý±â¿¡ ÇØ´çÇϴ û±¸Äڵ庰 °øÁö³»¿ëÀÌ ¾ø½À´Ï´Ù
|
|
|
|